Exercise, nutrition and enzyme replacement therapy are efficacious in adult Pompe patients: report from EPOC Consortium

  • Corrado Angelini | corrado.angelini@unipd.it Neuromuscular Laboratory, Department of Neurosciences, University of Padova, Padova, Italy.

Abstract

Pompe Disease, also known as glycogenosis type 2, is due to deficiency in lysosomal alpha- glucosidase, a lysosomal hydrolase, which presents infantile and late onset subtypes (LOPD). The myopathy in LOPD can be reversed by Enzyme Replacement Therapy (ERT), but might benefit from a concomitant low carbohydrate - high protein diet and aerobic exercise treatment. From 65 Late onset Pompe cases, we were able to obtain in 58 a self-reported evaluation, most of them gave a positive efficacy evaluation of Enzyme Replacement Therapy and they were classified by a self-administered scale as Responders or non-Responders. A cooperative study of a clinical group on LOPD monitored age, sex, BMI, Gardner-Medwin-Walton scale and six minute walking test (6MWT). The only clinical parameters that were significantly associated with a Responder category were the pre-ERT walking distance (p<0.035) and the use of regular diet, exercise or both (p<0.029). The present study shows that in LOPD this condition can be treated by ERT, but also benefits from concomitant diet and aerobic exercise therapy.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

References

Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC, Vulto AG, Cromme-Dijkhuis A, Weisglas-Kuperus N, Hop W, Van Hirtum H, Van Diggelen OP, Boer M, Kroos MA, Van Doorn PA, Van der Voort E, Sibbles B, Van Corven EJ, Brakenhoff JP, Van Hove J, Smeitink JA, de Jong G, Reuser AJ, Van der Ploeg AT. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics. 2004 May;113(5):e448-57. DOI: https://doi.org/10.1542/peds.113.5.e448

Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N, Levine J, Spencer C, McDonald M, Li J, Dumontier J, Halberthal M, Chien YH, Hopkin R, Vijayaraghavan S, Gruskin D, Bartholomew D, van der Ploeg A, Clancy JP, Parini R, Morin G, Beck M, De la Gastine GS, Jokic M, Thurberg B, Richards S, Bali D, Davison M, Worden MA, Chen YT, Wraith JE. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007 Jan 9;68(2):99-109. Erratum in: Neurology. 2008 Nov 18;71(21):1748. DOI: https://doi.org/10.1212/01.wnl.0000251268.41188.04

de Vries JM, van der Beek NA, Hop WC, Karstens FP, Wokke JH, de Visser M, van Engelen BG, Kuks JB, van der Kooi AJ, Notermans NC, Faber CG, Verschuuren JJ, Kruijshaar ME, Reuser AJ, van Doorn PA, van der Ploeg AT. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis. 2012 Sep 26;7:73. DOI: https://doi.org/10.1186/1750-1172-7-73

Güngör D, Kruijshaar ME, Plug I, D'Agostino RB, Hagemans ML, van Doorn PA, Reuser AJ, van der Ploeg AT. Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis. 2013 Mar 27;8:49. DOI: https://doi.org/10.1186/1750-1172-8-49

Toscano A, Schoser B. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol. 2013 Apr;260(4):951-9. DOI: https://doi.org/10.1007/s00415-012-6636-x

Barba-Romero MA, Barrot E, Bautista-Lorite J, Gutierrez-Rivas E, Illa I, Jimenez LM, Ley-Martos M, Lopez de Munain A, Pardo J, Pascual-Pascual SI, Perez-Lopez J, Solera J, Vilchez-Padilla JJ. Clinical guidelines for late-onset Pompe disease. Rev Neurol. 2012 Apr 16;54(8):497-507. English, Spanish. DOI: https://doi.org/10.33588/rn.5408.2012088

Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ, Kissel JT; AANEM Consensus Committee on Late-onset Pompe Disease. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve. 2012 Mar;45(3):319-33. DOI: https://doi.org/10.1002/mus.22329

Hundsberger T, Rohrbach M, Kern L, Rösler KM. Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease. J Neurol. 2013 Sep;260(9):2279-85. DOI: https://doi.org/10.1007/s00415-013-6980-5

Llerena JC Jr, Horovitz DM, Marie SK, Porta G, Giugliani R, Rojas MV, Martins AM; Brazilian Network for Studies in Pompe Disease (ReBrPOM). The Brazilian consensus on the management of Pompe disease. J Pediatr. 2009 Oct;155(4 Suppl):S47-56. DOI: https://doi.org/10.1016/j.jpeds.2009.07.006

Schüller A, Kornblum C, Deschauer M, Vorgerd M, Schrank B, Mengel E, Lukacs Z, Gläser D, Young P, Plöckinger U, Schoser B. Diagnose und Therapie des Late-onset-Morbus-Pompe [Diagnosis and therapy of late onset Pompe disease]. Nervenarzt. 2013 Dec;84(12):1467-72. German. DOI: https://doi.org/10.1007/s00115-013-3947-9

van der Ploeg AT, Kruijshaar ME, Toscano A, Laforêt P, Angelini C, Lachmann RH, Pascual Pascual SI, Roberts M, Rösler K, Stulnig T, van Doorn PA, Van den Bergh PYK, Vissing J, Schoser B; European Pompe Consortium. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol. 2017 Jun;24(6):768-e31. DOI: https://doi.org/10.1111/ene.13285

Angelini C, Semplicini C, Ravaglia S, Moggio M, Comi GP, Musumeci O, Pegoraro E, Tonin P, Filosto M, Servidei S, Morandi L, Crescimanno G, Marrosu G, Siciliano G, Mongini T, Toscano A; Italian Group on GSDII. New motor outcome function measures in evaluation of late-onset Pompe disease before and after enzyme replacement therapy. Muscle Nerve. 2012 Jun;45(6):831-4. DOI: https://doi.org/10.1002/mus.23340

Angelini C, Semplicini C, Pegoraro E. Clinical follow-up and efficacy evaluation in ERT. Advances in Diagnosis and Management of Glycogenosis II. Nova Science Publishers, Inc. Hauppauge, NY, USA. 2013; pp. 137-144.

Sechi A, Zuccarelli L, Grassi B, Frangiamore R, De Amicis R, Marzorati M, Porcelli S, Tullio A, Bacco A, Bertoli S, Dardis A, Biasutti L, Pasanisi MB, Devigili G, Bembi B. Exercise training alone or in combination with high-protein diet in patients with late onset Pompe disease: results of a cross over study. Orphanet J Rare Dis. 2020 Jun 6;15(1):143. DOI: https://doi.org/10.1186/s13023-020-01416-6

Angelini C, Semplicini C, Tonin P, Filosto M, Pegoraro E, Sorarù G, Fanin M. Progress in Enzyme Replacement Therapy in Glycogen Storage Disease Type II. Ther Adv Neurol Disord. 2009 May;2(3):143-53. DOI: https://doi.org/10.1177/1756285609103324

Slonim AE, Bulone L, Goldberg T, Minikes J, Slonim E, Galanko J, Martiniuk F. Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy. Muscle Nerve. 2007 Jan;35(1):70-7. DOI: https://doi.org/10.1002/mus.20665

Angelini C, Nascimbeni AC, Semplicini C. Therapeutic advances in the management of Pompe disease and other metabolic myopathies. Ther Adv Neurol Disord. 2013 Sep;6(5):311-21. DOI: https://doi.org/10.1177/1756285613487570

Angelini C, Semplicini C, Ravaglia S, Bembi B, Servidei S, Pegoraro E, Moggio M, Filosto M, Sette E, Crescimanno G, Tonin P, Parini R, Morandi L, Marrosu G, Greco G, Musumeci O, Di Iorio G, Siciliano G, Donati MA, Carubbi F, Ermani M, Mongini T, Toscano A; Italian GSDII Group. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol. 2012 May;259(5):952-8. DOI: https://doi.org/10.1007/s00415-011-6293-5

Vianello A, Semplicini C, Paladini L, Concas A, Ravaglia S, Servidei S, Toscano A, Mongini T, Angelini C, Pegoraro E. Enzyme replacement therapy improves respiratory outcomes in patients with late-onset type II glycogenosis and high ventilator dependency. Lung. 2013 Oct;191(5):537-44. DOI: https://doi.org/10.1007/s00408-013-9489-x

Ricci G, Baldanzi S, Seidita F, Proietti C, Carlini F, Peviani S, Antonini G, Vianello A, Siciliano G; Italian GSD II group. A mobile app for patients with Pompe disease and its possible clinical applications. Neuromuscul Disord. 2018 Jun;28(6):471-475. DOI: https://doi.org/10.1016/j.nmd.2018.03.005

Published
2021-05-03
Info
Issue
Section
Communications
Keywords:
Glycogenosis type 2, enzyme replacement therapy, exercise, nutrition
Statistics
  • Abstract views: 945

  • PDF: 249
  • HTML: 0
How to Cite
Angelini, C. (2021). Exercise, nutrition and enzyme replacement therapy are efficacious in adult Pompe patients: report from EPOC Consortium. European Journal of Translational Myology, 31(2). https://doi.org/10.4081/ejtm.2021.9798